Phase I multiple ascending-dose study of ICA 105665 in healthy volunteers.

Trial Profile

Phase I multiple ascending-dose study of ICA 105665 in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2010

At a glance

  • Drugs ICA 105665 (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Neusentis
  • Most Recent Events

    • 13 Sep 2010 Icagen has completed the conduct of the study at daily doses of 500mg and 600mg for a period of 7 days, according to a company issued media release. Analyses of the complete data are ongoing.
    • 27 Nov 2009 Results will be presented at the 63rd Annual Meeting of the American Epilepsy Society.
    • 17 Apr 2009 Results have been presented at the Antiepileptic Drug Trials X Conference in Coral Gables, Florida.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top